{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T07:49:01Z","timestamp":1773474541792,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"vor","delay-in-days":2524,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1111\/j.1469-0691.2007.01868.x","type":"journal-article","created":{"date-parts":[[2008,2,8]],"date-time":"2008-02-08T12:29:04Z","timestamp":1202473744000},"page":"175-180","source":"Crossref","is-referenced-by-count":42,"special_numbering":"S1","title":["Parenteral carbapenems"],"prefix":"10.1016","volume":"14","author":[{"given":"P.M.","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1469-0691.2007.01868.x_bib1","first-page":"387","article-title":"In vitro activity of thienamycin","volume":"3","author":"Shah","year":"1981","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1128\/AAC.12.3.406","article-title":"Binding of thienamycin and clavulanic acid to the penicillin-binding proteins of Escherichia coli K-12","volume":"12","author":"Spratt","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib3","series-title":"Antibiotiques agents antibact\u00e9s et antifongiques","first-page":"305","article-title":"Carbap\u00e9r\u00e8mes","author":"Bryskier","year":"1999"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib4","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jac\/dkg404","article-title":"Ertapenem, the first of a new group of carbapenems","volume":"52","author":"Shah","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib5","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1086\/319610","article-title":"New \u03b2-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy","volume":"32","author":"Bush","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib6","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00103-003-0693-3","article-title":"\u03b2-Laktamasen mit breitem Wirkungsspektrum","volume":"46","author":"Witte","year":"2003","journal-title":"Bundesgesundheitsbl \u2013 Gesundheitsforsch \u2013 Gesundheitschutz"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib7","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJMra041359","article-title":"The new beta-lactamases","volume":"352","author":"Jacoby","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum \u03b2-lactamases: a clinical update","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin Microbiol Rev"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib9","first-page":"179","article-title":"Resistenz bei h\u00e4ufig isolierten Enterobacteriaceae gegen\u00fcber Breitspektrum-Antibiotika","volume":"15","author":"Kresken","year":"2006","journal-title":"Chemother J"},{"issue":"suppl A","key":"10.1111\/j.1469-0691.2007.01868.x_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/24.suppl_A.31","article-title":"Comparative in-vitro activity of meropenem on clinical isolates from the United Kingdom","volume":"24","author":"King","year":"1989","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0732-8893(93)90039-A","article-title":"In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide","volume":"17","author":"Hoban","year":"1993","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib12","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1128\/AAC.45.6.1860-1867.2001","article-title":"In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia","volume":"45","author":"Livermore","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib13","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1128\/AAC.45.10.2831-2837.2001","article-title":"Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent \u03b2-lactamases","volume":"45","author":"Livermore","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib14","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ijantimicag.2006.05.031","article-title":"Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil","volume":"28","author":"Kiffer","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib15","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1128\/AAC.43.7.1669","article-title":"Roles of \u03b2-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae","volume":"43","author":"Martinez-Martinez","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib16","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(05)62567-6","article-title":"Emergence of a carbapenem-resistant Klebsiella pneumoniae","volume":"350","author":"MacKenzie","year":"1997","journal-title":"Lancet"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib17","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1086\/520214","article-title":"Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae","volume":"29","author":"Ahmad","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib18","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/jac\/46.6.895","article-title":"Emergence of imipenem resistance in Klebsiella pneumoniae owing to combination of plasmid-mediated CMY-4 and permeability alteration","volume":"46","author":"Cao","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1469-0691.2002.00401.x","article-title":"Emerging carbapenemases in Gram-negative aerobes","volume":"8","author":"Nordmann","year":"2002","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0732-8893(00)00222-4","article-title":"Carbapenem-resistant Serratia marcescens isolates producing Bush Group 2f \u03b2-lactamase (SME-1) in the United States: results from the MYSTIC Programme","volume":"39","author":"Gales","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/jac\/dkg103","article-title":"Production of CTX-M-3 extended-spectrum beta-lactamase and IMP-1 metallo beta-lactamase by five Gram-negative bacilli: survey of clinical isolates from seven laboratories collected in 1998 and 2000, in the Kinki region of Japan","volume":"51","author":"Yamasaki","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1086\/421495","article-title":"Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City","volume":"39","author":"Bradford","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib23","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1469-0691.2004.00913.x","article-title":"First identification of an Escherichia coli clinical isolate producing both metallo-beta-lactamase VIM-2 and extended-spectrum beta-lactamase IBC-1","volume":"10","author":"Galani","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib24","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jac\/dkh498","article-title":"IMP-1 metallo-beta-lactamase-producing Pseudomonas aeruginosa in a university hospital in the People's Republic of China","volume":"54","author":"Wang","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1086\/375594","article-title":"Clinical and bacteriological characteristics of IMP-type metallo-beta-lactamase-producing Pseudomonas aeruginosa","volume":"37","author":"Hirakata","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib26","first-page":"17","article-title":"VIM-metallo-beta-lactamase bei Pseudomonas aeruginosa","volume":"15","author":"Henrichfreise","year":"2006","journal-title":"Chemother J"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1469-0691.2005.01305.x","article-title":"Pandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomes","volume":"12","author":"Wang","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib28","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/jac\/dkm215","article-title":"Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 \u03b2-lactamases","volume":"60","author":"Lee","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.diagmicrobio.2006.07.011","article-title":"First national surveillance of susceptibility of extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel","volume":"57","author":"Colodner","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijantimicag.2006.09.006","article-title":"Reduced imipenem susceptibility in Klebsiella pneumoniae clinical isolates with plasmid-mediated CMY-2 and DHA-1 \u03b2-lactamases co-mediated by porin loss","volume":"29","author":"Lee","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib31","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ijantimicag.2006.11.020","article-title":"Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory","volume":"29","author":"Woodford","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib32","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1179\/joc.2002.14.4.346","article-title":"Antimicrobial-resistant Salmonella enterica serovars isolated from chickens in Spain","volume":"14","author":"Hernandez","year":"2002","journal-title":"J Chemother"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/jac\/dkh328","article-title":"CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa","volume":"54","author":"Thomson","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib34","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1128\/AAC.41.11.2352","article-title":"Carbapenem resistance in a clinical isolate of Citrobacter freundii","volume":"41","author":"Mainardi","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib35","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1086\/429822","article-title":"Escherichia coli: development of carbapenem resistance during therapy","volume":"40","author":"Hong","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib36","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1128\/AAC.49.4.1354-1358.2005","article-title":"Successive emergence of Enterobacter aerogenes strains resistant to imipenem and colistin in a patient","volume":"49","author":"Thiolas","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib37","first-page":"13","article-title":"Nachweis von zwei Carbapenem-resistenten Enterobacteriaceae-Isolaten in einem deutschen Krankenhaus","volume":"15","author":"Albert-Braun","year":"2006","journal-title":"Chemother J"},{"issue":"suppl 4","key":"10.1111\/j.1469-0691.2007.01868.x_bib38","first-page":"P1621","article-title":"Therapy-driven selection of carbapenem resistance in CTX-M-producing Klebsiella pneumoniae","volume":"12","author":"Pillay","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib39","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1128\/JCM.00418-06","article-title":"Characterization of a large outbreak by CTX-M-1-producing Klebsiella pneumoniae and mechanisms leading to in vivo carbapenem resistance development","volume":"44","author":"Mena","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib40","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1086\/503264","article-title":"In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase","volume":"42","author":"Elliott","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib41","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.2165\/00003495-200262150-00005","article-title":"Biapenem","volume":"62","author":"Perry","year":"2002","journal-title":"Drugs"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib42","first-page":"609","article-title":"Pharmacokinetics of imipenem\u2013cilastatin in serum and tissue","volume":"4","author":"K\u00fcmmel","year":"1985","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib43","first-page":"321","article-title":"Konzentrationen von Imipenem im Lungengewebe","volume":"2","author":"Unertl","year":"1986","journal-title":"FAC Fortschr Antimikrob Antineopl Chemother"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib44","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1128\/AAC.48.6.2228-2232.2004","article-title":"Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis","volume":"48","author":"Tomaselli","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib45","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00003088-200039030-00002","article-title":"Comparative pharmacokinetics of the carbapenems: clinical implications","volume":"39","author":"Mouton","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib46","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3109\/00365549609037949","article-title":"Biapenem versus imipenem\/cilastatin in the treatment of complicated intraabdominal infections: report from a Swedish Study Group","volume":"28","author":"Brismar","year":"1996","journal-title":"Scand J Infect Dis"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib47","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1086\/380645","article-title":"Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin","volume":"38","author":"Endimiani","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2007.01868.x_bib48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/420816","article-title":"Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases","volume":"39","author":"Paterson","year":"2004","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14604900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14604900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T19:46:30Z","timestamp":1557258390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14604900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":48,"alternative-id":["S1198743X14604900"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2007.01868.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}